Literature DB >> 10881258

Multiple sclerosis and antecedent infections: a case-control study.

R A Marrie1, C Wolfson, M C Sturkenboom, O Gout, O Heinzlef, E Roullet, L Abenhaim.   

Abstract

OBJECTIVES: To determine whether there is an excess of respiratory tract infections in the 5-week, 3-month, and 12-month periods before MS symptom onset and if there is an association between MS and a history of infectious mononucleosis (IM).
BACKGROUND: The etiology of MS remains unknown, but infection is frequently suggested as a putative etiologic agent. Epidemiologic studies have produced inconsistent evidence for an etiologic role of respiratory tract infections (RTI) and IM in MS.
METHODS: The authors performed a case-control study using the General Practice Research Database from the United Kingdom. There were 225 subjects with definite or probable MS, and 900 controls matched for age, sex, and physician practice. Using computerized patient records, the authors compared the mean rates of RTI per patient in the 5-week, 3-month, and 12-month periods before the date of onset of the first symptoms compatible with MS (index date). They also compared histories of IM.
RESULTS: In all periods, an increased frequency of RTI was associated with a significantly increased risk of MS. A history of IM was associated with greater than five times the risk of MS (OR = 5.5 [95% CI 1.5 to 19.7]).
CONCLUSIONS: These results support an association between a history of IM and subsequent MS. Respiratory tract infections may precipitate disease onset.

Entities:  

Mesh:

Year:  2000        PMID: 10881258     DOI: 10.1212/wnl.54.12.2307

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Infection as a cause of multiple sclerosis.

Authors:  Jock Murray
Journal:  BMJ       Date:  2002-11-16

2.  Multiple sclerosis and Epstein-Barr virus.

Authors:  Ruth Ann Marrie; Christina Wolfson
Journal:  Can J Infect Dis       Date:  2002-03

Review 3.  Environmental factors and their timing in adult-onset multiple sclerosis.

Authors:  Adam E Handel; Gavin Giovannoni; George C Ebers; Sreeram V Ramagopalan
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

4.  An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.

Authors:  Adam E Handel; Alexander J Williamson; Giulio Disanto; Lahiru Handunnetthi; Gavin Giovannoni; Sreeram V Ramagopalan
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

5.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

6.  Multiple sclerosis after infectious mononucleosis: record linkage study.

Authors:  Michael J Goldacre; Clare J Wotton; Valerie Seagroatt; David Yeates
Journal:  J Epidemiol Community Health       Date:  2004-12       Impact factor: 3.710

Review 7.  Potential triggers of MS.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Results Probl Cell Differ       Date:  2010

Review 8.  Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome.

Authors:  Diederik L H Koelman; Farrah J Mateen
Journal:  J Neurol       Date:  2015-03-13       Impact factor: 6.682

9.  The inflammasome pyrin contributes to pertussis toxin-induced IL-1β synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis.

Authors:  Aline Dumas; Nathalie Amiable; Juan Pablo de Rivero Vaccari; Jae Jin Chae; Robert W Keane; Steve Lacroix; Luc Vallières
Journal:  PLoS Pathog       Date:  2014-05-29       Impact factor: 6.823

10.  Characteristics in childhood and adolescence associated with future multiple sclerosis risk in men: cohort study.

Authors:  M Gunnarsson; R Udumyan; S Bahmanyar; Y Nilsagård; S Montgomery
Journal:  Eur J Neurol       Date:  2015-04-27       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.